Pomalidomide effective in reducing epistaxis in hereditary …
Oct 11, 2024 · 1. Among patients with hereditary hemorrhagic telangiectasia (HHT), pomalidomide significantly reduced the severity of epistaxis and improved quality of life. 2. Pomalidomide was associated with neutropenia, constipation, and rash. Evidence Rating Level: 1 (Excellent) Study Rundown: HHT is a common inheritable bleeding disorder characterized by fragile telangiectasias and arteriovenous ...
Mineralocorticoid receptor antagonists reduce hospitalizations in ...
Oct 18, 2024 · 1. Cardiovascular death and first heart failure hospitalization was reduced among HFrEF patients compared to HFmrEF and HFpEF patients. 2. Total heart failure hospitalizations were reduced in HFrEF compared to the other groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Mineralocorticoid receptor antagonists (MRAs) reduce hospitalizations and mortality in patients with heart failure ...
Ziresovir reduces the severity of respiratory syncytial virus in ...
Oct 11, 2024 · 1. Ziresovir, an antiviral drug targeted at respiratory syncytial virus (RSV), was superior to placebo in reducing signs and symptoms of hospitalized young children with RSV infection. 2. The incidence of adverse events was similar between ziresovir and placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: …
Using the DemRisk prediction model to indentify individuals at …
Oct 12, 2024 · 1. Predicting dementia in primary care settings for a 60-79 year old cohort should include age, history of stroke or epilepsy, gait problems, anticholinergic burden, use of SSRIs, receipt of social services, third-party involvement in consultations and a high number of missed primary care appointments. 2. Predicting dementia in primary care settings for a 60-79
Landmark Trials & Summaries: The Classics in Medicine - 2 Minute …
A deep understanding of these trials is paramount for every physician, healthcare professional, and trainee, as it lays the foundation for evidence-based clinical decisions made daily. 2MM+ Subscriber Exclusive Access: The Online Edition of The Classics Series™ includes The Classics in Medicine™ textbook and all deep-dive sub-specialty ...
Ponsegromab for the Treatment of Cancer Cachexia
Sep 23, 2024 · Tags: cancer cachexia GDF-15 ponsegromab. 1. Ponsegromab at increasing doses resulted in a mean increase in body weight compared to placebo; 1.22 kg (2.21%) in the 100-mg group, 1.92 kg (2.99%) in the 200-mg group, and 2.81 kg (5.46) in the 400-mg group. 2. Adverse events of any cause were reported in 67%-74% in the ponsegromab group vs 80% in.
Twice-yearly lenacapavir prevents HIV more effectively than daily …
Oct 15, 2024 · 1. In this randomized controlled trial, among adolescent girls and young women, it was found that twice-yearly lenacapavir resulted in a significantly reduced human immunodeficiency virus (HIV) incidence. 2. Lenacapavir was associated with more injection-site reactions than emtricitabine-tenofovir isopropyl fumarate (F/TDF) and tenofovir alafenamide with emtricitabine (F/TAF).
#VisualAbstract: Retatrutide reduces body weight by 17.5% in …
In the phase 2 clinical trial of Eli Lilly's retatrutide, the drug showed a notable weight reduction effect, with an average of 17.5% loss in body weight over a 24-week period. This investigational drug is distinctive in targeting GIP, GLP-1, and glucagon receptors, a novel approach compared to existing obesity treatments. The study, as reported
Perioperative pembrolizumab improves survival in resectable early …
Oct 17, 2024 · 1. 36-month overall survival and median event-free survival were significantly greater in the pembrolizumab group compared to control. 2. Grade 3-5 adverse events were comparable between both treatment groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Pembrolizumab combined with neoadjuvant chemotherapy has shown promise in improving event-free survival among patients with early ...
ANGPLT3 interfering RNA therapy reduces triglyceride levels in …
Oct 14, 2024 · 1. Zodasiran, an RNA interference (RNAi) therapy targeting angiopoietin-like 3 (ANGPTL3), resulted in a dose-dependent reduction in ANGPTL3 and triglyceride levels in patients with mixed hyperlipidemia. 2. Zodasiran also led to a dose-dependent reduction in other hyperlipidemic markers, including non-high-density lipoprotein cholesterol (non-HDLc) and low-density lipoprotein cholesterol (LDLc).